Compare DFDV & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DFDV | SEER |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.4M | 97.3M |
| IPO Year | 2022 | 2020 |
| Metric | DFDV | SEER |
|---|---|---|
| Price | $3.09 | $2.09 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $45.00 | N/A |
| AVG Volume (30 Days) | 539.9K | ★ 924.2K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.40 |
| EPS | N/A | ★ N/A |
| Revenue | $2,099,660.00 | ★ $16,578,000.00 |
| Revenue This Year | $32.58 | $2.14 |
| Revenue Next Year | $23.65 | $25.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 4.82 | ★ 16.99 |
| 52 Week Low | $2.44 | $1.55 |
| 52 Week High | $20.30 | $2.41 |
| Indicator | DFDV | SEER |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 46.48 |
| Support Level | $3.04 | $1.85 |
| Resistance Level | $3.35 | $2.09 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 71.74 | 27.78 |
DeFi Development Corp is a U.S. company committed to building its treasury around Solana (SOL), a fast-growing blockchain infrastructure platform. This equity delivers shareholders tangible exposure to SOL price movement and staking rewards, making the firm a proxy for the Solana ecosystem. The treasury extends to running its own validator infrastructure, allowing DFDV to actively participate in and benefit from the Solana network expansion. The firm has two segments: Digital Asset Treasury ("Treasury") and Real Estate Platform ("Real Estate"). The company generates the majority of its revenue from the Treasury segment.
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.